The Assessment of Cognitive Dysfunction in Major Depressive Disorder: A 16-Week Prospective Case-Control Study

Simple item page
dc.contributor.authorPoyraz Çökmüş F.
dc.contributor.authorMurat Özkan H.
dc.contributor.authorSücüllüoğlu-Dikici D.
dc.contributor.authorAşçibaşi K.
dc.contributor.authorAlçi D.
dc.contributor.authorAltunsoy N.
dc.contributor.authorKuru E.
dc.contributor.authorYüzeren S.
dc.contributor.authorAydemir Ö.
dc.date.accessioned2024-07-22T08:06:28Z
dc.date.available2024-07-22T08:06:28Z
dc.date.issued2021
dc.description.abstractObjective: Cognitive dysfunction is one of the core components of major depressive disorder (MDD). It is estimated that two-thirds of patients diagnosed with MDD have cognitive deficits. Cognitive symptoms are pervasive and affect functioning in several domains. This 16-week prospective case-control study aimed to assess the change of mood and cognitive symptoms during treatment. Materials and Methods: Ninety-eight patients with MDD and 113 healthy controls (HCs) participated in the study. The MDD group was evaluated 6 times (baseline, 2nd, 4th, 8th, 12th, and 16th weeks). For mood symptoms, the Montgomery-Asberg Depression Rating Scale was used, and for neurocognitive functions, the Perceived Deficits Questionnaire-Depression was used, and the Digit Symbol Substitution Test was administered to both groups. Results: At baseline, compared with the HCs, the neurocognitive function of patients with MDD was worse. From the 8th to the 16th week assessments, in both neurocognitive tests, the cognitive functions of patients with MDD had improved. Despite this improvement and the patients achieving remission, the patients’ cognitive performance did not improve to the level of the HC group at the 16th week. Conclusion: Our longitudinal research revealed that even though mood symptoms decreased and patients with depression did achieve symptomatic remission, their cognitive deficits perpetuated. © 2020, AVES. All rights reserved.
dc.identifier.DOI-ID10.5152/pcp.2021.20148
dc.identifier.issn24750573
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13545
dc.language.isoEnglish
dc.publisherAVES
dc.rightsAll Open Access; Gold Open Access
dc.subjectantihypertensive agent
dc.subjectserotonin noradrenalin reuptake inhibitor
dc.subjectserotonin uptake inhibitor
dc.subjectadult
dc.subjectArticle
dc.subjectBeck Depression Inventory
dc.subjectcase control study
dc.subjectcognition
dc.subjectcognitive defect
dc.subjectcognitive function test
dc.subjectcontrolled study
dc.subjectdepression
dc.subjectdigit symbol substitution test
dc.subjectfemale
dc.subjecthuman
dc.subjectlongitudinal study
dc.subjectmajor clinical study
dc.subjectmajor depression
dc.subjectmale
dc.subjectMontgomery Asberg Depression Rating Scale
dc.subjectmood
dc.subjectneuropsychological test
dc.subjectoscillation
dc.subjectPerceived Deficits Questionnaire-Depression
dc.subjectprospective study
dc.subjectpsychotherapy
dc.subjectquestionnaire
dc.subjectscoring system
dc.subjectsociodemographics
dc.titleThe Assessment of Cognitive Dysfunction in Major Depressive Disorder: A 16-Week Prospective Case-Control Study
dc.typeArticle

Files

Collections

Scopus Koleksiyonu